{"id":181819,"name":"ALLENA PHARMACEUTICALS","slug":"allena-pharmaceuticals","state":"MA","country":"United States of America","description":"Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders","totalSpending":90000,"filings":5,"yearlySpending":[{"year":2019,"income":90000},{"year":2020,"income":0}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"MED","display":"Medical/Disease Research/Clinical Labs"}],"firms":["THE PETRIZZO GROUP, INC."],"lobbyists":["TJ PETRIZZO","MEGAN PEREZ BURKE"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","White House Office"],"sampleDescriptions":["Advancing American Kidney Health Initiative","Advancing American Kidney Health Initiative","Advancing American Kidney Health Initiative","National Kidney Initiative -- Development of first in class therapeutics for patients with\nrare and severe metabolic disorders that affect the kidney.","National Kidney Initiative -- Development of first in class therapeutics for patients with\nrare and severe metabolic disorders that affect the kidney."]}